Östen Ljunggren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Östen Ljunggren has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Claes Ohlsson
Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2 shared publications - Elizabeth Barrett-Connor
University of California, San Diego
2 shared publications A Tosteson
MRC Epidemiology Resource Centre, University of Southampton, Southampton, United Kingdom
1 shared publication- Anders Larsson
Department of Medical Sciences, Uppsala University, Uppsala University Hospital, 75185 Uppsala, Sweden
1 shared publication - Anders Rönnblom
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
1 shared publication - Angela M. Cheung
Institute of Medical Science, University of Toronto
1 shared publication
Latest Publications
- Open Access
- 8 April 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (5)
Estimation of kidney function in Graves’ disease using creatinine and cystatin C
Introduction: There is no consensus regarding methods to estimate kidney function in hyperthyroidism. The aim was therefore to assess changes in filtration markers in patients with Graves’ disease undergoing treatment with antithyroid drugs. Methods: Thirty patients with de novo Graves’ disease were included. Blood sampling, including thyroid-stimulating hormone, fT3, fT4 and creatinine, was performed at baseline, 6 weeks, 3, 6, 12 and 24 months. Cystatin C was measured from frozen samples. To calculate creatinine- and cystatin C-based eGFR, the Lund–Malmö equation (LMR) and the CAPA formula were used. Results: fT3 and fT4 normalized during treatment. Creatinine increased initially but stabilized after 6 months. eGFRLMR decreased until 12 months. Cystatin C decreased, while eGFRCAPA and eGFRCAPA/eGFRLMR increased until 6 months. The mean of eGFRLMR and eGFRCAPA remained stable. The % changes in creatinine and cystatin C were associated with % changes in fT3 and fT4. In regression models including fT3 or fT4 with body weight (all % change), fT3 and fT4 were the strongest predictors of percentual changes in both creatinine and cystatin C. Conclusion: The increase in creatinine and decrease in cystatin C during the treatment of Graves’ disease was significantly associated with changes in thyroid hormones, and for creatinine, also body weight. The mean of eGFRLMR and eGFRCAPA remained stable, suggesting that creatinine and cystatin C were affected by different non-GFR-related factors. The potential use of eGFRLMR and eGFRCAPA to assess kidney function in patients with thyroid disorders should be further evaluated in studies measuring kidney function with state-of-the-art methods.
- 8 April 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (5)
Open AccessEstimation of kidney function in Graves’ disease using creatinine and cystatin C
Introduction: There is no consensus regarding methods to estimate kidney function in hyperthyroidism. The aim was therefore to assess changes in filtration markers in patients with Graves’ disease undergoing treatment with antithyroid drugs. Methods: Thirty patients with de novo Graves’ disease were included. Blood sampling, including thyroid-stimulating hormone, fT3, fT4 and creatinine, was performed at baseline, 6 weeks, 3, 6, 12 and 24 months. Cystatin C was measured from frozen samples. To calculate creatinine- and cystatin C-based eGFR, the Lund–Malmö equation (LMR) and the CAPA formula were used. Results: fT3 and fT4 normalized during treatment. Creatinine increased initially but stabilized after 6 months. eGFRLMR decreased until 12 months. Cystatin C decreased, while eGFRCAPA and eGFRCAPA/eGFRLMR increased until 6 months. The mean of eGFRLMR and eGFRCAPA remained stable. The % changes in creatinine and cystatin C were associated with % changes in fT3 and fT4. In regression models including fT3 or fT4 with body weight (all % change), fT3 and fT4 were the strongest predictors of percentual changes in both creatinine and cystatin C. Conclusion: The increase in creatinine and decrease in cystatin C during the treatment of Graves’ disease was significantly associated with changes in thyroid hormones, and for creatinine, also body weight. The mean of eGFRLMR and eGFRCAPA remained stable, suggesting that creatinine and cystatin C were affected by different non-GFR-related factors. The potential use of eGFRLMR and eGFRCAPA to assess kidney function in patients with thyroid disorders should be further evaluated in studies measuring kidney function with state-of-the-art methods.
- 8 August 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (11) , 1296-1303
Complications and adverse effects related to surgical and medical treatment in patients with inflammatory bowel disease in a prospectively recruited population-based cohort
Medical adverse effects and surgical complications have been reported during treatment of patients with inflammatory bowel diseases (IBDs). There is however a shortage of studies describing these i...
- 8 August 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (11) , 1296-1303
Complications and adverse effects related to surgical and medical treatment in patients with inflammatory bowel disease in a prospectively recruited population-based cohort
Medical adverse effects and surgical complications have been reported during treatment of patients with inflammatory bowel diseases (IBDs). There is however a shortage of studies describing these i...
- Open Access
- 30 March 2020
- Published by Springer Nature in Osteoporosis International
- Vol. 31 (8) , 1525-1533
Real-world effectiveness of osteoporosis treatment in the oldest old
Summary We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. Introduction To study real-world effectiveness of osteoporosis treatment on BMD and fractures in the oldest old women (≥ 80 years) compared with women (60–79 years) in the clinical setting using Swedish health register data. Methods National registers and data from DXA machines were used to study effectiveness of all available osteoporosis treatments in women 60–79 and ≥ 80 years using three approaches: (1) Total Hip BMD change up to 8 years after treatment start; (2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start with the subsequent 12 months; and (3) comparison of fracture incidence post-fracture in women ≥ 80 years treated with osteoporosis treatment or calcium/vitamin D. Results Analysis 1: Total Hip BMD increased by up to 6.7% and 7.7% in women 60–79 and ≥ 80 years old, respectively. The mean increase in BMD was 1.1%-units per year in both age groups. Analysis 2: Relative to the 3-month baseline, fracture incidence decreased during the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral, and non-hip-non-vertebral fracture, respectively. Analysis 3: A 24-month incidence of any fracture in women ≥ 80 years given post-fracture osteoporosis treatment was lower (HR = 0.78) than in women given calcium/vitamin D, but treatment allocation was not random, with lower mortality (HR = 0.51) in patients receiving OP treatment. Conclusions Osteoporosis medication in women > 80 years in clinical practice likely works, and the magnitude of effect is similar to what was estimated in younger women. The choice between osteoporosis treatment and calcium/vitamin D after fracture in women ≥ 80 years is not random but appears associated with the patient’s health status and presence of vertebral fractures, rather than the known risk profile of sustaining a fracture at a high age.
- 30 March 2020
- Published by Springer Nature in Osteoporosis International
- Vol. 31 (8) , 1525-1533
Open AccessReal-world effectiveness of osteoporosis treatment in the oldest old
Summary We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. Introduction To study real-world effectiveness of osteoporosis treatment on BMD and fractures in the oldest old women (≥ 80 years) compared with women (60–79 years) in the clinical setting using Swedish health register data. Methods National registers and data from DXA machines were used to study effectiveness of all available osteoporosis treatments in women 60–79 and ≥ 80 years using three approaches: (1) Total Hip BMD change up to 8 years after treatment start; (2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start with the subsequent 12 months; and (3) comparison of fracture incidence post-fracture in women ≥ 80 years treated with osteoporosis treatment or calcium/vitamin D. Results Analysis 1: Total Hip BMD increased by up to 6.7% and 7.7% in women 60–79 and ≥ 80 years old, respectively. The mean increase in BMD was 1.1%-units per year in both age groups. Analysis 2: Relative to the 3-month baseline, fracture incidence decreased during the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral, and non-hip-non-vertebral fracture, respectively. Analysis 3: A 24-month incidence of any fracture in women ≥ 80 years given post-fracture osteoporosis treatment was lower (HR = 0.78) than in women given calcium/vitamin D, but treatment allocation was not random, with lower mortality (HR = 0.51) in patients receiving OP treatment. Conclusions Osteoporosis medication in women > 80 years in clinical practice likely works, and the magnitude of effect is similar to what was estimated in younger women. The choice between osteoporosis treatment and calcium/vitamin D after fracture in women ≥ 80 years is not random but appears associated with the patient’s health status and presence of vertebral fractures, rather than the known risk profile of sustaining a fracture at a high age.
- Open Access
- 4 May 2010
- Published by Springer Nature in Osteoporosis International
- Vol. 21 (S1) , 7-24
IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
- 4 May 2010
- Published by Springer Nature in Osteoporosis International
- Vol. 21 (S1) , 7-24
Open AccessIOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
- 1 June 2009
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 10 (2) , e268
Abstract: 524 LOW SERUM LEVELS OF DHEA PREDICT DEATH FROM CARDIOVASCULAR DISEASE IN OLDER MEN
- 1 June 2009
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 10 (2) , e268
Abstract: 524 LOW SERUM LEVELS OF DHEA PREDICT DEATH FROM CARDIOVASCULAR DISEASE IN OLDER MEN